Brian Edd

Q: What is Brian Edd email address?

Email Brian Edd at brian.mullinax@att.net. This email is the most updated Brian Edd email found in 2026.

Q: How to contact Brian Edd?

To contact Brian Edd send an email to brian.mullinax@att.net. If you want to call Brian Edd try calling on +13177331213 and +13178730956.

Market Access and Reimbursement Advisor at Biopharmaceutical Organization | Zionsville, Indiana, United States

About Brian Edd

Brian Edd serves as a pivotal Market Access and Reimbursement Advisor at a leading biopharmaceutical organization, where he plays a crucial role in ensuring that novel medical devices and biopharmaceuticals receive timely coverage consideration. With a focus on oral oncolytic orphan drugs currently in the pipeline, Brian leads market access planning efforts that are integral to the product's successful launch. His expertise lies in aligning product development with the anticipated payer environment, ensuring that the innovative therapies not only meet clinical needs but also address the complexities of reimbursement landscapes.

In his current role, Brian is actively involved in strategic clinical trial design and tactical launch planning, aimed at securing FDA Breakthrough Therapy designation. By leveraging his deep understanding of managed care and pharmaceutical sales, he provides invaluable insights to development teams, helping them navigate payer concerns and the current standard of care. His ability to research and communicate payer and stakeholder perspectives on related diseases allows him to identify critical issues that may impact reimbursement strategies.

Brian's skill set encompasses strategic business plan development, regulatory compliance, and performance metric reporting, which he utilizes to establish best practices within the organization. His global experience enhances his capability to identify policies and procedures that facilitate provider uptake and optimize reimbursement processes. By focusing on patient outcomes, Brian ensures that the biopharmaceuticals not only meet regulatory standards but also deliver real-world value, ultimately improving access to life-saving therapies for patients in need.

Brian Edd Work